白细胞介素12基因治疗小鼠变应性鼻炎的实验研究

Effect of intranasal interleukin-12 gene therapy for allergic rhinitis in murine model

目的探讨鼻腔局部应用EB病毒(Epstein-Barrvirus,EBV)质粒载体介导的白细胞介素12(interleukin-12,IL-12)基因治疗对变应性鼻炎炎症反应的调节作用。方法将36只6～8周雄BALB/C实验小鼠随机分为变应性鼻炎组、IL-12基因治疗组和正常对照组,每组12只。以BALB/c小鼠经卵清蛋白(ovalbumin,OVA)免疫建立变应性鼻炎模型,用阳离子脂质体包裹EBV质粒载体介导的IL-12表达质粒(pGEG.mI-L12)形成混合物EBV/lipoplex,于激发前鼻腔局部滴入后,观察小鼠变应性症状的改善情况,并检测该基因在3组实验鼠鼻黏膜局部的表达情况以及对鼻黏膜炎性细胞和Th2细胞因子的影响。结果基因治疗组小鼠鼻黏膜中IL-12mRNA阳性细胞数量明显高于变应性鼻炎组,差异有统计学意义(P<0.01);基因治疗组小鼠鼻黏膜中IL12阳性细胞数量明显高于变应性鼻炎组(P<0.05);变应性鼻炎组鼻黏膜中嗜酸粒细胞、肥大细胞和IL5阳性细胞比例显著高于基因治疗组和正常对照组(P<0.01);变应性鼻炎组外周血中总IgE含量显著高于正常对照组和基因治疗组(F=1216.21,P<0.01)。结论鼻腔局部应用EBV/lipoplex后,pGEG.mIL-12能够在鼻黏膜中高效地表达,能明显抑制鼻腔的变应性反应。EBV/lipoplex有望成为变应性鼻炎免疫治疗一种新的方法。

Objective To investigate whether the local application of IL-12 gene with EBV-plasmid vector to nasal mucosa couldprevent allergic inflammation in murine allergic rhinitis model. Methods(Thirty-six )BALB/C mice were randomly divided into allergic rhinitis group gene therapy group and control group. In mice with OVA-induced allergic rhinitis, the EBV/lipoplex (a novel cationic lipid combined with EBV-plasmid vector, pGEG.mIL-12) was locally administered into nasal mucosa before OVA challenge. The expression of IL-12 mRNA and protein, the change of eosinophilia and mast cell, and Th2 cytokine production in the nasal mucosa were measured. Results The amounts of IL-12 mRNA positive cells and IL-12 positive cells in nasal mucosa of gene therapy group were significantly higher than that of allergic rhinitis group (P<0.01 and P<0.05) .The amount of eosinophils, mast cells ,and the level of IL-5 expression in nasal mucosa in allergic rhinitis group were significantly higher than those in gene therapy group and control group (P<0.01). The level of total IgE of peripheral blood in allergic rhinitis group was significantly higher than that in gene therapy group and control group (F=1216.21,P<0.01). Conclusions These findings indicated that IL-12 mRNA and protein were expressed effectively after the local administration of pGEG.mIL-12 in the nasal mucosa. The local application of pGEG.mIL-12 is effective in modulating nasal allergic response and may be a convenient method for future approach to allergic rhinitis.